| - |
Eculizumab |
Soliris® |
For the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in the Irish healthcare setting. |
Assessment process complete |
14th October 2013 |
 |
| - |
Edoxaban |
Lixiana® |
For the prevention of stroke/SE in adults with NVAF and for the treatment/secondary prevention of DVT and PE in adults. |
Rapid review complete |
10th July 2015 |
|
| 23026 |
Efgartigimod alfa |
Vyvgart® |
Efgartigimod alfa is indicated as an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis who are anti-acetylcholine receptor antibody positive. |
Awaiting full HTA submission from Applicant |
7th November 2023 |
|
| 22072 |
Eladocagene exuparvovec |
Upstaza® |
For the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L-amino acid decarboxylase (AADC) deficiency with a severe phenotype. |
__ |
23rd December 2022 |
|
| 25005 |
Elafibranor |
Iqirvo® |
Elafibranor (Iqirvo®) is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. |
Rapid Review Complete |
13th March 2025 |
|
| - |
Elbasvir 50mg/100mg grazoprevir |
Zepatier® |
For the treatment of genotypes 1 and 4 chronic HCV infection in patients with Child-Turcotte-Pugh score A (CTPA) |
Rapid review complete |
13th October 2016 |
|
| - |
Eliglustat |
Cerdelga® |
For the long-term treatment of adult patients with Gaucher disease type 1. |
Assessment process complete |
25th April 2018 |
|
| - |
Elosulfase alfa |
Vimzim® |
For the treatment of mucopolysaccharidosis, type IVA (Morquio A syndrome, MPS IVA) in patients of all ages. |
Assessment process complete |
8th December 2016 |
|
| 23066 |
Elranatamab |
Elrexfio® |
Elranatamab (Elrexfio®) is indicated as monotherapy for the treatment of adult patients with relapsed, refractory multiple myeloma, who have received at least three prior therapies (including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody) and have demonstrated disease progression on the last therapy. |
NCPE Assessment Process Complete |
1st July 2025 |
|
| - |
Eltrombopag |
Revolade® |
For the treatment of chronic immune thrombocytopenic purpura (ITP) |
Assessment process complete |
4th November 2010 |
|
| - |
Eltrombopag |
Revolade® |
For adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy |
Rapid review complete |
14th February 2014 |
|
| - |
Eltrombopag |
Revolade® |
For the treatment adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation. |
Assessment process complete |
2nd March 2016 |
|
| - |
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide |
Genvoya® |
For the treatment of adults and adolescents infected with human immunodeficiency virus – 1 (HIV-1). |
Rapid review complete |
6th January 2016 |
|
| - |
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumerate) |
Stribild® |
For the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to the three antiretroviral agents in Stribild®. |
Rapid review complete |
20th May 2013 |
|
| - |
Empagliflozin |
Jardiance® |
Add-on combination therapy: In combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. Monotherapy: When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance. |
Rapid review complete |
17th June 2014 |
|
| 21030 |
Empagliflozin |
Jardiance® |
For the treatment of symptomatic chronic heart failure with reduced ejection fraction. |
NCPE Assessment Process Complete |
28th April 2022 |
|
| 24042 |
Empagliflozin |
Jardiance® |
Empagliflozin is indicated in adults for the treatment of chronic kidney disease. |
Rapid Review Complete |
22nd November 2024 |
|
| 22068 |
Empagliflozin |
Jardiance® |
For the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40% |
Rapid review complete |
20th October 2023 |
|
| - |
Emtricitabine / tenofovir disoproxil fumarate |
Truvada® |
In combination with safer sex practices for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. |
Awaiting Applicant submission |
18th July 2017 |
|
| - |
Emtricitabine/tenofovir alafenamide |
Descovy® |
In combination with other antiretroviral agents (ARVs) for the treatment of adults and adolescents (≥12 years; body weight ≥35 kg) infected with human immunodeficiency virus (HIV) type 1 |
Rapid review complete |
26th April 2016 |
|
| - |
Emtricitabine/tenofovir disoproxil |
TEVA® |
For pre-exposure prophylaxis in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults in high risk |
Rapid review complete |
22nd December 2017 |
|
| 24011 |
Enalapril maleate |
Aqumeldi® |
For the treatment of heart failure in children and adolescents from birth to less than 18 years of age. |
Rapid Review complete |
12th April 2024 |
|
| 20037 |
Encorafenib |
Braftovi® |
In combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, who have received prior systemic therapy |
Assessment process complete |
28th January 2022 |
|
| - |
Encorafenib, binimetinib |
Braftovi®, Mektovi® |
For the treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation. |
Rapid review complete |
23rd January 2019 |
|
| 22024 |
Enfortumab vedotin |
Padcev® |
As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC) who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor |
NCPE Assessment Process Complete |
14th March 2024 |
|
| 24038 |
Enfortumab vedotin in combination with pembrolizumab |
Padcev®in combination with Keytruda® |
Enfortumab vedotin in combination with pembrolizumab is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy. |
Full HTA submission received from Applicant |
13th March 2025 |
|
| 21038 |
Entrectinib |
Rozlytrek® |
As monotherapy for the treatment of patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors |
Rapid review complete |
28th September 2021 |
|
| 22055 |
Entrectinib |
Rozlytrek® |
As monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor and who have no satisfactory treatment options |
Rapid review complete |
29th September 2022 |
|
| - |
Enzalutamide |
Xtandi® |
First line treatment of adult men with mCRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated |
Assessment process complete |
22nd June 2015 |
|
| 21022 |
Enzalutamide |
Xtandi® |
For the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy. |
Rapid review complete |
7th July 2021 |
|
| 18056 |
Enzalutamide |
Xtandi® |
For the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). |
Assessment process complete |
24th May 2022 |
|
| - |
Enzalutamide |
Xtandi® |
For the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed on or after docetaxel therapy. |
Assessment process complete |
10th April 2014 |
|
| 24010 |
Epcoritamab |
Tepkinly® |
Epcoritamab (Tepkinly®) is indicated as monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. |
Full HTA submission received from Applicant |
23rd January 2025 |
|
| 24047 |
Eplontersen |
Wainzua® |
Eplontersen (Wainzua®) is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy. |
Rapid Review Complete |
19th December 2024 |
|
| - |
Epoprostenol |
Veletri® |
For the treatment of pulmonary arterial hypertension (PAH) (idiopathic or heritable PAH and PAH associated with connective tissue diseases) in patients with WHO FC III–IV symptoms to improve exercise capacity |
Rapid review complete |
7th February 2017 |
|
| 22052 |
Eptinezumab |
Vyepti® |
For the prophylaxis of migraine in adults who have at least four migraine days per month |
Rapid review complete |
20th October 2023 |
|
| 24034 |
Erdafitinib |
Balversa® |
Erdafitinib monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. |
Rapid Review Complete |
17th September 2024 |
|
| - |
Erenumab |
Aimovig® |
For the treatment of chronic and episodic migraine in adults who have at least 4 migraine days per month when initiating treatment with erenumab. |
Assessment process complete |
30th September 2019 |
|
| - |
Eribulin |
Halaven® |
For the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments. |
Assessment process complete |
7th December 2012 |
|
| - |
Ertugliflozin |
Steglatro® |
For the treatment of the treatment 2 diabetes mellitus (T2DM) in individuals 18 years and over to improve glycaemic control. |
Rapid review complete |
21st May 2018 |
|
| 19055 |
Esketamine |
Spravato® |
In combination with a SSRI or SNRI is indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current depressive episode |
Assessment process complete |
9th March 2021 |
|
| - |
Eslicarbazepine |
Zebinix® |
For the treatment of Epilepsy |
Rapid review complete |
1st September 2009 |
|
| 20013 |
Estradiol |
Oestrogel® Pump Gel |
For: Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women; Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. |
Rapid review complete |
9th April 2020 |
|
| 22071 |
Estriol |
Blissel® |
Estriol (Blissel®) 50 micrograms per gram is indicated for local treatment of vaginal dryness in post- menopausal women with vaginal atrophy. |
Rapid Review Complete |
23rd January 2023 |
|
| - |
Etanercept |
Benepali® |
A biosimilar of the TNF-α inhibitor Etanercept (Enbrel®) for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, axial spondylitis and plaque psoriasis. |
Rapid review complete |
30th May 2016 |
|
| - |
Etelcalcitide |
Parsabiv® |
For the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis. |
Rapid review complete |
1st September 2017 |
|
| 24012 |
Etrasimod |
(Velsipity® |
Etrasimod (Velsipity®) is indicated for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent. |
Rapid Review Complete |
7th May 2024 |
|
| - |
Everolimus |
Afinitor® |
Treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor |
Rapid review complete |
15th October 2012 |
|
| - |
Everolimus |
Votubia® |
For the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with TSC. |
Rapid review complete |
26th April 2017 |
|
| - |
Everolimus |
Votubia® |
For the treatment of patients aged 3 years and older with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery |
Rapid review complete |
14th October 2011 |
|
